Antibodies and immunotoxins that target human glycoprotein NMB

US8039593B2 · kind B2 · utility

Assignees

• Duke University · US
• The United States of America, as represented by the Secretary, Health and Human Services · US

Inventors

• Chien-Tsun Kuan · Cary, US
• Darell Bigner · Mebane, US
• Ira H. Pastan · Potomac, US

Key dates

• Filing date: Oct 31, 2006
• Grant date: Oct 18, 2011
• Expiry date: Jul 10, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/565
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides high affinity antibodies suitable for forming immunotoxins that inhibit the growth of cells expressing human glycoprotein NMB, including glioblastoma multiform cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells, oligodendroglioma cells, and melanoma cells.